<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Obstet Gynecol</journal-id><journal-title>Infectious Diseases in Obstetrics and Gynecology</journal-title><issn pub-type="ppub">1064-7449</issn><issn pub-type="epub">1098-0997</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">12839630</article-id><article-id pub-id-type="pmc">1852268</article-id>
            <article-id pub-id-type="pii">S1064744903000048</article-id>
            <article-id pub-id-type="doi">10.1155/S1064744903000048</article-id>
      <article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Ertapenem Once a Day Versus Piperacillin&#x02013;Tazobactam Every
6 Hours for Treatment of Acute Pelvic Infections:
A Prospective, Multicenter, Randomized, Double-Blind Study</article-title></title-group><contrib-group>
            <contrib contrib-type="author"><name><surname>Roy</surname><given-names>Subir</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
            <contrib contrib-type="author"><name><surname>Higareda</surname><given-names>Iliana</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
            <contrib contrib-type="author"><name><surname>Angel-Muller</surname><given-names>Edith</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib>
            <contrib contrib-type="author"><name><surname>Ismail</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib>
            <contrib contrib-type="author"><name><surname>Hague</surname><given-names>Caren</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
            <contrib contrib-type="author"><name><surname>Adeyi</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
            <contrib contrib-type="author" corresp="yes"><name><surname>Woods</surname><given-names>Gail L.</given-names></name><address><email>gail_woods@merck.com</email></address><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref></contrib>
            <contrib contrib-type="author"><name><surname>Teppler</surname><given-names>Hedy</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
      </contrib-group>
            <aff id="aff1"><label>1</label>
                <addr-line>Keck School of Medicine at USC</addr-line>
                <addr-line>Los Angeles</addr-line>
                <addr-line>CA</addr-line>
                <country>USA</country>
            </aff>
            <aff id="aff2"><label>2</label>
                <addr-line>Nuevo Hospital Civil</addr-line>
                <addr-line>Guadalajara</addr-line>
                <country>Mexico</country>
            </aff>
            <aff id="aff3"><label>3</label>
                <addr-line>Universidad Nacional de Colombia</addr-line>
                <addr-line>Bogota</addr-line>
                <country>Colombia</country>
            </aff>
            <aff id="aff4"><label>4</label>
                <addr-line>University of Chicago</addr-line>
                <addr-line>Chicago</addr-line>
                <addr-line>IL</addr-line>
                <country>USA</country>
            </aff>
            <aff id="aff5"><label>5</label>
                <addr-line>Merck Research Laboratories</addr-line>
                <addr-line>West Point</addr-line>
                <addr-line>PA</addr-line>
                <country>USA</country>
            </aff>
            <aff id="aff6"><label>6</label>
                <addr-line>Merck &#x00026;Co., Inc.</addr-line>
                <addr-line>10 Sentry Parkway</addr-line>
                <addr-line>BL 3-4</addr-line>
                <addr-line>Blue Bell</addr-line>
                <addr-line>PA</addr-line>
                <addr-line>19422</addr-line>
                <country>USA</country>
            </aff>
        <pub-date pub-type="ppub"><year>2003</year></pub-date><volume>11</volume><issue>1</issue><fpage>27</fpage><lpage>37</lpage><history><date date-type="received"><day>26</day><month>6</month><year>2002</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2002</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2003 Hindawi Publishing Corporation.</copyright-statement><copyright-year>2003</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract>
                            <p><italic>Objective:</italic> To compare ertapenem therapy with piperacillin&#x02013;tazobactam therapy for the management of acute
pelvic infections.</p>
<p><italic>Methods:</italic> In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of
two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then
randomized to ertapenem, 1 g once a day, or piperacillin&#x02013;tazobactam, 3.375 g every 6 hours, both administered
intravenously.</p>
<p><italic>Results:</italic> In total, 163 patients in the ertapenem group and 153 patients in the piperacillin&#x02013;tazobactam group were
clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common
single pathogen was <italic>Escherichia coli</italic> . At the primary efficacy endpoint 2&#x02013;4 weeks post therapy, 93.9% of patients
who received ertapenem and 91.5% of those who received piperacillin&#x02013;tazobactam were cured (95%
confidence interval for the difference, adjusting for strata, &#x02013;4% to 8.8%), indicating that cure rates for both
treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by
stratum and severity of infection. The frequency and severity of drug-related adverse events were generally
similar in both groups.</p>
<p><italic>Conclusions:</italic>  In this study, ertapenem was as effective as piperacillin&#x02013;tazobactam for the treatment of acute pelvic
infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin&#x02013;tazobactam.</p>
                        </abstract></article-meta></front></article>


